Form 4: Karyopharm Therapeutics Director Deepika Pakianathan Granted Stock Options

Karyopharm Therapeutics Inc. director Deepika Pakianathan was granted 4,600 nonstatutory stock options with an exercise price of $4.48, reflecting a recent reverse stock split.

Summary

• Deepika Pakianathan, a Director of Karyopharm Therapeutics Inc. (KPTI), was granted 4,600 nonstatutory stock options on May 28, 2025.
• The options have an exercise price of $4.48 per share.
• The options are set to vest 100% on May 28, 2026.
• The expiration date for these options is May 27, 2035.
• All reported amounts in this Form 4 reflect the one-for-fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event that aligns director interests with shareholders, but it doesn't convey significant new operational or financial news.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• This is a routine compensation event for a director, indicating standard corporate governance practices.

Risks

• The value of the stock options is subject to the future performance of Karyopharm Therapeutics Inc.'s stock price, which carries inherent market risk.
• The options' value could be diluted by future equity issuances, although this specific filing does not indicate such plans.

Future Outlook

The granted stock options are scheduled to fully vest on May 28, 2026, indicating a future milestone for the reporting person's equity compensation.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, used to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term success of the company.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule (100% after one year) is a common structure for director equity grants, aiming to retain the director's service for at least that period.

Corporate Governance

Related Party Transactions

• The grant of stock options to Deepika Pakianathan, a director of Karyopharm Therapeutics Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing share value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The granted options will vest on May 28, 2026, at which point Deepika Pakianathan will be able to exercise them.

Key Dates

Keywords

Karyopharm Therapeutics, KPTI, Form 4, Stock Option, Insider Transaction, Director Compensation, Equity Grant, Reverse Stock Split